AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30610502 — intervention group
Group type: COMPARATOR
Intervention: Control (recanalization alone)
Number of subjects: 400
Study 27435886 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% glucose
Number of subjects: 94
Study 27435886 — intervention group
Group type: COMPARATOR
Intervention: 24% sucrose
Number of subjects: 94
Study 26199693 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Cycler SeptiFast (LC-SF) test
Number of subjects: 86
Study 26199693 — intervention group
Group type: COMPARATOR
Intervention: Blood culture (BC)
Number of subjects: 86
Study 23275433 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing eye goggles and earmuffs for a 4‐hour period in the NICU
Number of subjects: 54
Study 23275433 — intervention group
Group type: COMPARATOR
Intervention: Control period (no eye goggles and earmuffs)
Number of subjects: 54
Study 21802081 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet with supplemental virgin olive oil (VOO)
Number of subjects: 187
Study 21802081 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet with supplemental nuts
Number of subjects: 187
Study 21802081 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 187
Study 19365152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract patients
Number of subjects: 69
Study 19365152 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma patients
Number of subjects: 69
Study 19365152 — intervention group
Group type: COMPARATOR
Intervention: Overall correlation
Number of subjects: 69
Study 16919531 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/d, 12 weeks)
Number of subjects: 20
Study 15023777 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 488
Study 11371410 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Mycobacterium vaccae (0.5 mg)
Number of subjects: 43
Study 11371410 — intervention group
Group type: EXPERIMENTAL
Intervention: Delipidated deglycolipidated Mycobacterium vaccae (DDMV) (0.05 mg)
Number of subjects: 43
Study 11371410 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (placebo)
Number of subjects: 43
Study 9418711 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized normal saline
Number of subjects: 35
Study 9418711 — intervention group
Group type: COMPARATOR
Intervention: Heparinized culture medium
Number of subjects: 35
Study 8105829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 16
Study 8105829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31364105 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Soft gels technology
Number of subjects: 85
Study 31364105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 85
Study 28850362 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 15mg
Number of subjects: 50
Study 28850362 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 50
Study 26083699 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week guided skiing program
Number of subjects: 26
Study 26083699 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) instructed not to change daily routines and not allowed to ski
Number of subjects: 26
Study 23280514 — intervention group
Group type: EXPERIMENTAL
Intervention: MJ-dependent group
Number of subjects: 59
Study 23280514 — intervention group
Group type: COMPARATOR
Intervention: Non-MJ-dependent group
Number of subjects: 59
Study 23280514 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59
Study 21585703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Number of subjects: 105
Study 21585703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 105
Study 21585703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 18326964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose diuretic
Number of subjects: 0
Study 18326964 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple medications
Number of subjects: 0
Study 17042849 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 60
Study 17042849 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study 12747879 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL670 at 10 mg x kg(‐1) x day(‐1)
Number of subjects: 24
Study 12747879 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL670 at 20 mg x kg(‐1) x day(‐1)
Number of subjects: 24
Study 12747879 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL670 at 40 mg x kg(‐1) x day(‐1)
Number of subjects: 24
Study 12747879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10815250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of C. sempervirens and C. japonica extracts
Number of subjects: 0
Study 8623996 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (increased at 1% per min)
Number of subjects: 23
Study 8623996 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (increased at 0.5% per min)
Number of subjects: 23
Study 8623996 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (increased at 0.16% per min)
Number of subjects: 23
Study 8623996 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (both groups)
Number of subjects: 23
Study 8623996 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 23
Study 1455882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic conditions (39.5 degrees C)
Number of subjects: 10
Study 1455882 — intervention group
Group type: COMPARATOR
Intervention: Normothermic conditions (37 degrees C)
Number of subjects: 10
Study 6397330 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide plus 50 mg triamterene
Number of subjects: 20
Study 6397330 — intervention group
Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide plus 5 mg amiloride
Number of subjects: 20
Study 30738698 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT)
Number of subjects: 46
Study 30738698 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 46
Study 28590992 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 120
Study 28590992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26051494 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol-enriched beverage (IEB) containing 2.23 g of inositols in 250 ml
Number of subjects: 40
Study 26051494 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-sweetened beverage (SB)
Number of subjects: 40
Study 25456755 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin
Number of subjects: 70
Study 25456755 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/day atorvastatin
Number of subjects: 70
Study 22345434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing ergometry and biweekly strength training
Number of subjects: 27
Study 22345434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing ergometry and biweekly strength training with volume loading
Number of subjects: 27
Study 22345434 — intervention group
Group type: COMPARATOR
Intervention: Sedentary bed rest
Number of subjects: 27
Study 22345434 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone (Rowing ergometry and strength training)
Number of subjects: 27
Study 20830491 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam group (50 μg/kg midazolam added to 3 mg/kg lidocaine 2% w/v)
Number of subjects: 40
Study 20830491 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 mg/kg lidocaine 2% w/v diluted with saline to 40 ml)
Number of subjects: 40
Study 20830491 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam group
Number of subjects: 40
Study 17580330 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB)
Number of subjects: 22
Study 17580330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15912389 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors
Number of subjects: 5462
Study 12479119 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 227
Study 12479119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone
Number of subjects: 227
Study 12479119 — intervention group
Group type: EXPERIMENTAL
Intervention: Viagra
Number of subjects: 227
Study 12479119 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment + Viagra
Number of subjects: 227
Study 12479119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral PGE1
Number of subjects: 227
Study 12479119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection
Number of subjects: 227
Study 9656089 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-administered rating scales (LSAS, BSPS, Fear Questionnaire)
Number of subjects: 0
Study 9656089 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-administered rating scales
Number of subjects: 0
Study 7584286 — intervention group
Group type: EXPERIMENTAL
Intervention: High imagery text
Number of subjects: 0
Study 7584286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low imagery text
Number of subjects: 0
Study 7584286 — intervention group
Group type: EXPERIMENTAL
Intervention: Imageability manipulated within-subjects
Number of subjects: 0
Study 7584286 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to high imagery text
Number of subjects: 0
Study 7584286 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to low imagery text
Number of subjects: 0
Study 2744903 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg/day)
Number of subjects: 13
Study 2744903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1089401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 1089401 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 1089401 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 0
Study 30829962 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET), n = 14
Number of subjects: 28
Study 30829962 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC), n = 14
Number of subjects: 28
Study 30829962 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Qc
Number of subjects: 28
Study 30829962 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Volume (SV) during exercise
Number of subjects: 28
Study 30829962 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting left ventricular ejection fraction
Number of subjects: 28
Study 30829962 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain
Number of subjects: 28
Study 30829962 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin levels
Number of subjects: 28
Study 27654852 — intervention group
Group type: EXPERIMENTAL
Intervention: PR1 peptide vaccine (0.25, 0.5 or 1.0 mg, administered subcutaneously every 3 weeks)
Number of subjects: 66
Study 27654852 — intervention group
Group type: EXPERIMENTAL
Intervention: PR1 peptide vaccine
Number of subjects: 66
Study 25764483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser (LLL)
Number of subjects: 21
Study 25764483 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing paste (DP) containing 8% arginine-calcium carbonate
Number of subjects: 21
Study 25764483 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser followed by desensitizing paste (LLL+DP)
Number of subjects: 21
Study 25764483 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing paste followed by laser (DP+LLL)
Number of subjects: 21
Study 25764483 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 21
Study 23661722 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in inoperable cohort
Number of subjects: 971
Study 23661722 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in paradoxical low-flow cohort
Number of subjects: 971
Study 23661722 — intervention group
Group type: COMPARATOR
Intervention: Medical management in inoperable cohort
Number of subjects: 971
Study 23661722 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement
Number of subjects: 971
Study 21084649 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise before protein intake
Number of subjects: 0
Study 21084649 — intervention group
Group type: COMPARATOR
Intervention: Rest before protein intake
Number of subjects: 0
Study 20128231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with monomeric allergoid at a dosage of 1000 AU five times a week for two years
Number of subjects: 40
Study 20128231 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug therapy)
Number of subjects: 40
Study 16924050 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based intervention materials encouraging communication about skin cancer risks and promoting sun-safe behaviors.
Number of subjects: 340
Study 16924050 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention materials provided).
Number of subjects: 340
Study 12761456 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic pacing in study group (11 patients)
Number of subjects: 19
Study 12761456 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic pacing in healthy volunteers
Number of subjects: 19
Study 12761456 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 patients, no pacing)
Number of subjects: 19
Study 11061104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 55
Study 11061104 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 55
Study 8956810 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 81
Study 8956810 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 81
Study 1388220 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined oestradiol valerate/cyproterone acetate (2 mg E2V + 1 mg CPA daily)
Number of subjects: 49
Study 3895386 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy combined with medical treatment for IBS
Number of subjects: 204
Study 3895386 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy combined with medical treatment for PUD
Number of subjects: 204
Study 3895386 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only for IBS
Number of subjects: 204
Study 3895386 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only for PUD
Number of subjects: 204
Study 31135633 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroflexed Viewing (RV) using the RetroView colonoscope
Number of subjects: 225
Study 31135633 — intervention group
Group type: COMPARATOR
Intervention: Forward Viewing (FV)
Number of subjects: 225
Study 31135633 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward Viewing (FV) and Retroflexed Viewing (RV)
Number of subjects: 225
Study 28870196 — intervention group
Group type: EXPERIMENTAL
Intervention: Email elicitation
Number of subjects: 15
Study 28870196 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face elicitation
Number of subjects: 15
Study 25659440 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TXA) administration: bolus dose of 15 mg/kg 10 min before tourniquet inflation, intra-articular administration of 3 grams 10 min before tourniquet deflation, IV infusion of 10 mg/kg/h for 3 h after completion on the second side.
Number of subjects: 0
Study 25659440 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TXA) administration
Number of subjects: 0
Study 25659440 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25058218 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus, 7.5 mg/d
Number of subjects: 546
Study 25058218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 22334768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg
Number of subjects: 1055
Study 22334768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 200/10 μg
Number of subjects: 1055
Study 22334768 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 400 μg
Number of subjects: 1055
Study 22334768 — intervention group
Group type: COMPARATOR
Intervention: Formoterol (F) 10 μg
Number of subjects: 1055
Study 22334768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1055
Study 19243713 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d for 8 weeks
Number of subjects: 18
Study 19243713 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d for 8 weeks (subgroup of clinically responsive patients)
Number of subjects: 18
Study 19243713 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (untreated)
Number of subjects: 18
Study 17435976 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of ACEI therapy (premed group)
Number of subjects: 100
Study 17435976 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of ACEI therapy (withdrawal group)
Number of subjects: 100
Study 15385353 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol MCT/LCT (group M; n = 109)
Number of subjects: 222
Study 15385353 — intervention group
Group type: COMPARATOR
Intervention: Standard propofol LCT with 20 mg lidocaine (group L; n = 113)
Number of subjects: 222
Study 15385353 — intervention group
Group type: COMPARATOR
Intervention: Standard propofol LCT with 20 mg lidocaine (group L)
Number of subjects: 222
Study 15385353 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol MCT/LCT (group M)
Number of subjects: 222
Study 11238801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) at doses between 2.4 and 7.2 g/d
Number of subjects: 34
Study 11238801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE)
Number of subjects: 34
Study 11238801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) at 7.2 g/d
Number of subjects: 34
Study 11238801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) at all levels of supplementation
Number of subjects: 34
Study 11238801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9792483 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally loaded film stimuli (amusement and disgust)
Number of subjects: 0
Study 9792483 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction time (RT) task
Number of subjects: 0
Study 9792483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor (CP) task
Number of subjects: 0
Study 7639417 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (300 mg)
Number of subjects: 12
Study 7639417 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (600 mg)
Number of subjects: 12
Study 7639417 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (1200 mg)
Number of subjects: 12
Study 7639417 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 2502040 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) 20 mg p.o. (five doses during 30 hr preceding ethanol intake)
Number of subjects: 11
Study 2502040 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 1 g/kg p.o. during 1 hr
Number of subjects: 11
Study 2502040 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 11
Study 2502040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 943420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ppm NO2 exposure
Number of subjects: 20
Study 943420 — intervention group
Group type: COMPARATOR
Intervention: Unpolluted air exposure
Number of subjects: 20
Study 943420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ppm NO2 exposure
Number of subjects: 20
Study 31953832 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent attached to Foley catheter and removed together
Number of subjects: 163
Study 31953832 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy for stent removal
Number of subjects: 163
Study 31535460 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine (ARG: 3.2 g)
Number of subjects: 27
Study 31535460 — intervention group
Group type: EXPERIMENTAL
Intervention: wheat protein hydrolysate (WPH: 2 g) + l-arginine (ARG: 3.2 g)
Number of subjects: 27
Study 28002542 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with 24 different talkers
Number of subjects: 64
Study 28002542 — intervention group
Group type: EXPERIMENTAL
Intervention: Passage-based transcription training
Number of subjects: 64
Study 28002542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence-based single-talker training
Number of subjects: 64
Study 28002542 — intervention group
Group type: COMPARATOR
Intervention: Control (transcribing unvocoded sentence materials)
Number of subjects: 64
Study 26030264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 96
Study 26030264 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 96
Study 23848096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamb consumption (Ternasco de Aragón)
Number of subjects: 50
Study 23848096 — intervention group
Group type: COMPARATOR
Intervention: Chicken-based diet
Number of subjects: 50
Study 22013950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 1150
Study 22013950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1150
Study 19385031 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day energy restrictive diet
Number of subjects: 20
Study 19385031 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day energy balanced diet
Number of subjects: 20
Study 19385031 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast preload followed by lunch request
Number of subjects: 20
Study 19385031 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction
Number of subjects: 20